Li Zhang, PhD (she/her/hers)

Daiichi Sankyo

Dr. Li Zhang is currently a Director, Quantitative Clinical Pharmacology at Daiichi Sankyo. She earned her M.D. from Peking University and Ph.D. from University at Buffalo. Dr. Zhang has successfully contributed to multiple successful NDA/BLA regulatory submission/approvals, including Dupixent® for Asthma and CRSwNP, etc. Dr. Zhang have accumulated extensive expertise in implementing novel quantitative clinical pharmacology, translational science and clinical science approaches to improve decision making during early- and late-stage clinical drug development for small molecules, RNA based therapies and biologics, including bispecifics, antibodies and enzyme replacement therapies across multiple therapeutic area. Dr. Zhang has contributed to more than 60 publications in Clin Pharm field.

Presentation(s):

• Transformative Advancements in the Treatment of Immune-Mediated Diseases: Integrating Patient-Centric Clinical Pharmacology with Translational MID3 for Biologics

  Thursday, May 29, 2025
  9:30 AM - 10:30 AM East Coast USA Time